Therefore, the formed Fe3O4-PEG-CD56/Avastin@Ce6 NPs were synthesized to label NK-92 cells for their targeted delivery to breast cancer cells, which would facilitate targeted therapy and non-invasive imaging of breast cancer by NK-92 cell. This evidence concerns the gene NCAM1 and breast cancer.